Testing a new liver medicine in people with fatty liver
Part of Digestive system clinical trials.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be in the right age range: 18–55 (healthy adults) or 18–65/18–75 (MASLD groups).
- Have the right body size: BMI limits apply (different ranges for East Asians vs other ethnicities).
- If you’re in the MASLD parts: have at least 8.5% liver fat on an MRI scan (MRI-PDFF).
- For healthy-adult group only: you must meet strict Japanese background and recent Japan-residency rules.
- Be able to take required tests, including MRI (if you’re in the MASLD parts).
- Avoid major exclusion factors, such as abnormal liver blood tests, hepatitis B/C or HIV, smoking recently, heavy alcohol/drug abuse, or recent major weight change.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.